BioVie files prospectus supplement for up to $25M ATM; already raised $59.4M from 8.1M shares

BIOVIE INC.

Filed prospectus supplement under new shelf registration (333-274083) for continued at-the-market sales of common stock.
As of Jan 19, 2024, issued 8,136,058 shares under existing Sales Agreement with Cantor Fitzgerald for net proceeds of $59.4M.
Commissions and expenses totaled ~$1.8M; new shelf effective Aug 28, 2023 replaces expiring Feb 2, 2024 shelf.
Up to $25M aggregate offering price authorized under the new supplement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.